Obefazimod
Obefazimod is an investigational new drug that is being evaluated for the treatment of ulcerative colitis. It is miR-124 micro RNA upregulator. Obefazimod was developed by the French biotech company Abivax SA, whose shares rose by more than 500% when the phase 3 data showed promising results.